Background Sacubitril/valsartan improves outcome in patients with heart failure (HF) with
reduced left ventricular (LV) ejection fraction (EF, HFrEF). However, little is known about …

Background Previous studies and case-series showed improvement in left ventricular (LV)
function and reverse remodeling after sacubitril/valsartan therapy in real-world studies. We …

Background Observational studies have demonstrated that treatment with
sacubitril/valsartan may improve left ventricular (LV) systolic and diastolic function in …

Aims The study aims to explore the real‐world titration patterns of sacubitril/valsartan in a
chronic heart failure (HF) follow‐up management system and the effect on the recovery of …

Sacubitril/valsartan has been shown to improve clinical outcomes in patients with heart
failure and reduced ejection fraction (HFrEF), but its effects on left ventricular (LV) systolic …

Background: The aim of this study was to observe the effect of Sacubitril/Valsartan on
cardiac function and remodeling in patients with heart failure with reduced ejection fraction …

Background The angiotensin receptor-neprilysin inhibitor sacubitril/valsartan is known to
improve outcomes of cardiac death and hospitalization due to heart failure in patients with …

Aims We evaluated the clinical outcomes and trajectory of cardiac reverse remodelling
according to the timing of sacubitril/valsartan (Sac/Val) use in patients with heart failure (HF) …

Background Literature describing recovery of left ventricular (LV) function post
sacubitril/valsartan treatment and the optimal management of heart failure (HF) patients …

Background Limited evidence is available regarding low (24/26 mg) and middle (49/51 mg)
doses of sacubitril/valsartan. Objectives The purpose of this study was to investigate the …